AcouSort
AcouSort develops, produces and sells standalone laboratory products and integrated OEM solutions.
- Company typePublic
- Founded2010
- HeadquartersLund, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AcouSort does
AcouSort develops, produces and sells standalone laboratory products and integrated OEM solutions where ultrasound is used to separate, wash and enrich cells, exosomes and other biological particles for research and diagnostics. The company is based on commercializing the research within acoustofluidics from the world renowned group of professor Thomas Laurell at the Department of Biomedical Engineering (BME) at Lund University, Sweden.
AcouSort firmographics
Firmographics- Name
- AcouSort
- Legal name
- AcouSort AB
- Website
- https://acousort.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AcouSort develops, produces and sells standalone laboratory products and integrated OEM solutions.
- Ownership category
- akta.pro rank
AcouSort industry classification
Industry- Product category
- Acoustofluidic sample preparation instruments and OEM modules
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Apparatus & Furniture (3821)
- akta.pro primary industry
- Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD)
- akta.pro secondary industry
- General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens) (HLAGAIAC)
Keywords
Where AcouSort is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
AcouSort business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Product Sales - Research Instruments: Sale of AcouTrap and AcouWash benchtop research instruments. These instruments are used for sample preparation and serve as platforms for developing applications while also generating direct revenue.
- Sample Preparation Modules: Separation modules, trapping modules, and other components sold to diagnostic system manufacturers for integration into their products. Core commercialization strategy through OEM partnerships.
- Evaluation Kits: Evaluation kits sold to companies wanting to evaluate technology for integration into their prototype systems before committing to formal partnerships.
- Licensing Royalties - Werfen Agreement: License and distribution agreement with Werfen for GEM Premier 7000 blood-gas analyzer. Werfen prepays minimum royalties (approximately USD 1.3 million in 2026 including 2027-2028 prepayment). Original agreement signed in spring 2018. Hemolysis detection based on AcouSort acoustofluidic technology.
- Feasibility Projects and Collaboration Revenue: Revenue from feasibility projects with potential partners. Initial feasibility project with global manufacturer expected to generate USD 40,000. Extension of pharma company lease valued at EUR 11,300.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | AcouTrap System - Research Instrument |
| One time/ perpetual license | Pay-as-you-go | AcouWash System - Research Instrument |
| Unit Pricing | Pay-as-you-go | Evaluation Kits |
| Unit Pricing | Pay-as-you-go | Separation Modules and Components |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
AcouSort product offering
Product offeringCore offering
AcouSort develops, produces, and sells standalone laboratory products and integrated OEM solutions based on proprietary acoustofluidics technology. The portfolio includes two benchtop research instruments (AcouTrap and AcouWash) and four sample preparation modules (Separation Module, Trapping Module, AQC Module, and AcouPlasmaOptical) that enable automated, label-free, and gentle separation, washing, up-concentration, and optical analysis of cells, extracellular vesicles, bacteria, and blood plasma for diagnostic system manufacturers, cell therapy companies, flow cytometry users, and research institutions.
Product overview
AcouSort provides acoustofluidic solutions for diagnostic applications and cell therapy manufacturing. The product portfolio consists of two benchtop research instruments (AcouTrap and AcouWash) and four sample preparation modules (Separation Module, Trapping Module, AQC Module, and AcouPlasmaOptical) designed for OEM integration into third-party diagnostic and life science systems. The instruments serve as research platforms using 96-well microplate formats, while the modules provide embedded sample processing capabilities for integration into manufacturers' products. Evaluation kits enable potential partners to assess the technology before committing to development partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- AcouTrap Benchtop research instrument for automated sample preparation of cells, extracellular vesicles, and bacteria from different media, operating on a standard 96-well microplate format with capacity of up to 48 samples per plate for rapid, high-quality output.
- AcouWash Benchtop research instrument for label-free separation of target cells from various samples using gentle automated processing ideal for sensitive separations and handling fragile cells without loss in viability, producing high-quality samples with minimal variation.
- Separation Module OEM module for integration in-line with sample flow to provide continuous separation, washing, or up-concentration of cells; ideal for automation of sample processing in systems for cell therapy manufacturing, stem cell isolation, flow cytometry, or sample preparation platforms.
- Trapping Module OEM module for integration in-line with sample flow to provide continuous capturing of particles or cells, seamlessly integrating into microfluidic cell sorters or quality control systems for bioreactors and cell therapy production.
- AQC Module OEM module for in-line optical analysis of particle suspensions, enabling non-invasive optical access to the dispersing medium in a mixed suspension by momentarily separating the solid phase from the medium, ideal for Quality Control or Monitoring applications.
- AcouPlasmaOptical OEM module from the AcouPlasma concept that enables in-line analysis of blood plasma from whole blood samples using proprietary acoustic forces combined with microfluidics, eliminating the need for centrifugation for point-of-care blood gas and diagnostic workflows.
- Evaluation Kits Pre-configured kits sold to companies evaluating AcouSort's technology for integration into their prototype systems before committing to formal product development and OEM partnerships.
- Joint Development Custom development service for integrating AcouSort's acoustic cell processing technology into third-party systems, targeting manufacturers of life-science or diagnostic instrumentation seeking unique sample processing capabilities.
Quantifiable outcome
- 44.7% increase in net revenues from SEK 4.7 to SEK 6.9 million in 2025
- +4 more outcomes
Companies that use AcouSort
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles4 records
AcouSort technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
AcouSort partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor, core and important.
- Global Manufacturing Company (unnamed)minorFeasibility project with large international manufacturing company investigating applicability of AcouSort's technology for removing particles in different steps of production workflows. First feasibility project includes pre-study and delivery of two prototype devices for evaluation. Expected revenue USD 40,000. If results positive, potential for long-term collaboration developing inline solution for production process.
- MFXcoreCollaboration with UK-based MFX, developer of next-generation scalable bioreactor platforms (Cyto Engine), to evaluate if AcouSort's technology can be paired with MFX's platform and workflow to streamline cell therapy manufacturing. MFX leads the EcoCAR Consortium, a multi-million-pound UK government-funded project under the Sustainable Medicines Manufacturing Programme. AcouSort acts as sub-supplier to develop cell collection and purification processes. Aims to reduce sample processing times, cut operational costs, and decrease environmental burden of producing CAR-T cell therapies.
- SeeQ DiagnosticscoreTechnology evaluation agreement with Danish diagnostics company for evaluation of AcouSort's blood/plasma separation technology for automatic preparation of blood samples for SeeQ's SepSeeQ diagnostic platform. Solution includes a generally applicable interface unit that can be mounted on a standard pipetting robot with AcouSort's acoustic separation modules for blood/plasma separation. SeeQ Diagnostics is supported by BioInnovation Institute in Copenhagen.
- UK-based Sepsis Treatment Company (unnamed)minorFeasibility project started March 2025 to explore feasibility of AcouSort's technology for improved management of sepsis patient treatment. First part of study involves lease of AcouWash system for evaluating automated solution for sample preparation.
- Bio-RecellminorLetter of intent signed March 2025 to jointly explore developing a system for automated clean-up and isolation of stem cells and immune cells from adipose tissue. Core technology based on AcouSort's unique acoustofluidic expertise combined with Bio-Recell's efficient digestion and isolation capabilities.
- Leading Global Pharma Company (unnamed)coreCollaboration to explore potential of AcouWash technology in partnering company's QC procedures. Initial evaluation in R&D setting highly successful. Partner decided to prolong evaluation with another six months (April 2025 extension). Total value of extension EUR 11,300. Pending finalization study results, pursuing extension for long-term implementation.
- Moeller MedicalimportantGerman developer and manufacturer of high-precision medical solutions. Collaboration initiated in 2024, extended when German company ordered additional separation modules for clean-up of fluid samples for integration into research prototypes. Moeller Medical exhibited prototype system including AcouSort's AcouWash technology at Analytica trade fair in Munich (March 24-27, 2026). Company founded in 1949, headquartered in Fulda, Germany, specializing in aesthetic surgery, CSF management, and fluid management systems.
- Central European Diagnostic Company (unnamed)importantMultiple orders from Central European company developing diagnostic systems and medical devices. Collaboration initiated mid-2024 with evaluation kit order, followed by additional separation module orders for evaluating broader feasibility. Third order in September 2025 included driven modules and separation modules for prototype development and product design process.
- WerfencoreLicense and distribution agreement originally signed in spring 2018. AcouSort's acoustofluidic technology implemented in Werfen's GEM Premier 7000 blood gas analyzer for hemolysis detection. The system delivers complete blood-gas results (pH, pO2, pCO2, sodium, potassium, ionized calcium, chloride, glucose, lactate, hematocrit, total hemoglobin, total bilirubin, CO-Oximetry) in 45 seconds with automatic hemolysis detection. Amendment signed March 2026 for prepayment of royalties. Total approximately USD 1.3 million payable to AcouSort in early 2026.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
AcouSort competitors and assessment
Company assessmentDirect peers
- NanoCellect Biomedical: Developer of microfluidic cell sorting instruments for life science research and clinical diagnostics. Directly comparable to AcouSort as a microfluidics-based cell handling platform targeting flow cytometry and cell therapy research customers.
- Cytonome/ST: Engineers cell sorting and processing solutions for cell therapy manufacturing and clinical research. Comparable to AcouSort's OEM business model of providing integrated modules for cell therapy and high-value cell applications.
- Standard BioTools (formerly Fluidigm): Microfluidics-based mass cytometry and cell biology instruments for life science research. Directly comparable acoustofluidics/microfluidics technology stack serving overlapping research and clinical customers.
- Bruker (formerly PhenomeX / Berkeley Lights): Provides cell biology and cell therapy manufacturing workflow platforms including Beacon instrument. Comparable to AcouSort's modular cell handling and quality control value proposition for cell therapy developers.
- Fluigent: Specializes in microfluidic flow control and liquid handling for life science and diagnostics. Comparable component-level microfluidic technology and OEM integration focus.
- Miltenyi Biotec: Provides automated cell separation and processing instruments for cell therapy manufacturing and clinical research. Comparable to AcouSort's cell therapy and diagnostic sample preparation modules.
Broad incumbents
- Sony Biotechnology (CGX10): Major flow cytometry and cell sorting instrument vendor with deep life science and clinical installed base. Comparable as a broader incumbent in cell analysis instrumentation that AcouSort's modules could integrate with.
- Bio-Rad Laboratories: Global life science research and clinical diagnostics manufacturer with extensive flow cytometry, digital PCR, and lab automation portfolio. Comparable as a broad incumbent that competes for OEM/customer attention in the cell handling space.
- Beckman Coulter Life Sciences (Danaher): Major flow cytometry and laboratory automation provider with global commercial reach. Comparable as a broad incumbent in cell sorting and biomedical sample preparation.
- MilliporeSigma (Merck KGaA Life Science): Broad laboratory products, bioprocessing, and lab automation solutions provider. Comparable as a large incumbent in the upstream/downstream bioprocessing and laboratory consumables markets where AcouSort competes for OEM partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AcouSort social profiles
Digital presenceAcouSort financial estimates
Financial estimateRevenue estimate
Valuation estimate
AcouSort leadership team
Management profileNumber of profiles
Profiles9 records
AcouSort funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AcouSort M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AcouSort
What does AcouSort do?
AcouSort develops, produces, and sells standalone laboratory products and integrated OEM solutions based on proprietary acoustofluidics technology. The portfolio includes two benchtop research instruments (AcouTrap and AcouWash) and four sample preparation modules (Separation Module, Trapping Module, AQC Module, and AcouPlasmaOptical) that enable automated, label-free, and gentle separation, washing, up-concentration, and optical analysis of cells, extracellular vesicles, bacteria, and blood plasma for diagnostic system manufacturers, cell therapy companies, flow cytometry users, and research institutions.
Is AcouSort a public or private company?
AcouSort is a public company. It is classified as public and is currently operating.
When was AcouSort founded?
AcouSort was founded in 2010. It employs 11 to 50 people.
Where is AcouSort based?
AcouSort is headquartered in Lund, Sweden, in the Europe region.
How does AcouSort make money?
Five revenue lines are on record. Product Sales - Research Instruments are the primary driver. The others are sample Preparation Modules, evaluation Kits, licensing Royalties - Werfen Agreement and feasibility Projects and Collaboration Revenue.
Who are AcouSort's main competitors?
Direct peers on record are NanoCellect Biomedical, Cytonome/ST, Standard BioTools (formerly Fluidigm), Bruker (formerly PhenomeX / Berkeley Lights), Fluigent and Miltenyi Biotec. Broad incumbents are Sony Biotechnology (CGX10), Bio-Rad Laboratories, Beckman Coulter Life Sciences (Danaher) and MilliporeSigma (Merck KGaA Life Science).
Does AcouSort have an API?
No public API is recorded for AcouSort.
What industry is AcouSort in?
AcouSort's product category is Acoustofluidic sample preparation instruments and OEM modules. Its primary akta.pro industry code is HLAGAIAD, Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations), with a secondary code of HLAGAIAC, General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens). Its NAICS code is 334510 and its SIC code is 3845.